Lichen International Ltd

INDEX TO INTERIM UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 F-2

Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss for the six months ended June 30, 2026 and 2025 F-3

Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity for the six months ended June 30, 2026 and 2025 F-4

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 F-5

Notes to Unaudited Condensed Consolidated Financial Statements F-6

AS OF JUNE 30, 2026 AND DECEMBER 31, 2025

(All amounts in thousands of USD, except for share and per share data, unless otherwise noted)

As of June 30, 2026 As of December 31, 2025

Accounts receivable and contract assets 1,931 2,260

Prepayments, deposits, and other current assets 3,088 6,992

Accrued expenses and other current liabilities 3,320 3,404

Class A Ordinary Share, $ 0.008 par value, 20,000,000,000 shares authorized; 16,216,825 shares issued and outstanding 1 130 130

Class B Ordinary Share, $ 0.008 par value, 5,000,000,000 shares authorized; 110,000 shares issued and outstanding 1 1 1

Additional paid-in capital 51,251 51,251

Accumulated other comprehensive loss ( 816 ) ( 2,690 )

Total shareholders' equity 60,875 70,550

Total liabilities and shareholders' equity $ 65,290 $ 75,573

1 On March 3, 2025, the Company consolidated (each a "Share") its common shares on the basis of 200 pre-consolidation Shares for one (1) post-consolidation share, which was approved by the Board on February 10, 2025. Share amounts have been retrospectively restated to reflect the post-consolidation number of shares.

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

(All amounts in thousands of USD, except for share and per share data, unless otherwise noted)

Financial and taxation solution services $ 8,053 $ 11,579

Software and maintenance services 1,271 1,330

Selling and marketing ( 4,815 ) ( 5,910 )

General and administrative ( 7,794 ) ( 5,932 )

Total operating expenses ( 12,609 ) ( 11,842 )

Loss before income taxes ( 11,536 ) ( 9,094 )

Less: Net income attributable to non-controlling interests - 174

Net loss attributable to Lichen International Limited ( 11,549 ) ( 9,356 )

Foreign currency translation adjustments 1,874 154

Weighted average number of ordinary shares outstanding - basic and diluted 1 16,326,825 282,846

Loss per ordinary share - basic and diluted 1 ( 0.71 ) ( 32.46 )

1 On March 3, 2025, the Company consolidated (each a "Share") its common shares on the basis of 200 pre-consolidation Shares for one (1) post-consolidation share, which was approved by the Board on February 10, 2025. Share amounts have been retrospectively restated to reflect the post-consolidation number of shares.

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(All amounts in thousands of USD, except for share and per share data, unless otherwise noted)

FOR THE SIX MONTHS ENDED JUNE 30, 2026 and 2025

1 On March 3, 2025, the Company consolidated (each a "Share") its common shares on the basis of 200 pre-consolidation Shares for one (1) post-consolidation share, which was approved by the Board on February 10, 2025. Share amounts have been retrospectively restated to reflect the post-consolidation number of shares.